Mast cell sarcoma of the scalp: the first sign of undisclosed systemic mastocytosis?

Pathol Res Pract

Department of Biomorphological and Functional Science, Section of Anatomic Pathology, Federico II University, Via Pansini 5, 80131 Naples, Italy.

Published: November 2012

Mastocytosis is a neoplastic disease of mast cells and their CD34+ precursors, including a heterogeneous group of disorders. It is characterized by abnormal growth and accumulation of mast cells in one or more organ systems. Mast cell sarcoma is an extremely rare and aggressive disease characterized by local proliferation of atypical mast cells, destructive growth and poor prognosis, without systemic involvement. Very few clinical cases describing this entity have been reported in the literature. In this paper, we report a case of a mast cell sarcoma, localized in the scalp of a 63-year-old woman; it appears to be the first manifestation of undisclosed systemic mastocytosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2012.06.010DOI Listing

Publication Analysis

Top Keywords

mast cell
12
cell sarcoma
12
mast cells
12
undisclosed systemic
8
mast
6
sarcoma scalp
4
scalp sign
4
sign undisclosed
4
systemic mastocytosis?
4
mastocytosis? mastocytosis
4

Similar Publications

Background: IgE-mediated food allergy is accompanied by mucosal mast cell (MMC) hyperplasia in the intestinal mucosa. Intestinal MMC numbers correlate with the severity of food allergy symptoms. However, the mechanisms by which MMCs proliferate excessively are poorly understood.

View Article and Find Full Text PDF

Two-pore channel regulators - Who is in control?

Front Physiol

January 2025

Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Ludwig-Maximilians-University, Munich, Germany.

Two-pore channels (TPCs) are adenine nucleotide and phosphoinositide regulated cation channels. NAADP activates and ATP blocks TPCs, while the endolysosomal phosphoinositide PI(3,5)P activates TPCs. TPCs are ubiquitously expressed including expression in the innate as well as the adaptive immune system.

View Article and Find Full Text PDF

Background: Myasthenia gravis (MG) and idiopathic inflammatory myopathies (IIM) are autoimmune disorders that can co-occur, complicating diagnosis and treatment. The molecular mechanisms underlying this comorbidity are not well understood.

Objective: This study aims to identify common differentially expressed genes (co-DEGs) between MG and IIM to elucidate shared pathogenic pathways and potential therapeutic targets.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!